Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Daily News

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

Todd Neale

December 26, 2025

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

L.A. McKeown

October 27, 2025

News Conference News CX Symposium 2025

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

L.A. McKeown

April 24, 2025

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

L.A. McKeown

November 11, 2024

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

News Conference News VIVA 2023

New Carotid Stent Systems Associated With Low Stroke Risk

L.A. McKeown

November 09, 2023

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

L.A. McKeown

October 25, 2023

News Daily News

CMS Issues Proposed Coverage Decision to Broaden Access for Carotid Stenting

L.A. McKeown

July 12, 2023

News Conference News SCAI 2022

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

L.A. McKeown

May 23, 2022

News Daily News

FDA Advisors Unconvinced by Lutonix BTK Drug-Coated Balloon

L.A. McKeown

February 18, 2021

News Conference News VIVA 2020

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

L.A. McKeown

November 11, 2020

News Conference News TCT 2020

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

L.A. McKeown

October 18, 2020

News Daily News

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

L.A. McKeown

June 29, 2020

News Conference News CRT 2020

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

Michael O'Riordan

February 28, 2020

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

L.A. McKeown

November 06, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

L.A. McKeown

March 01, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

Many Invasive Procedures, Including Cardiovascular, Up Risk of Infective Endocarditis

Caitlin E. Cox

June 11, 2018

Advertisement

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

New Carotid Stent Systems Associated With Low Stroke Risk

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

CMS Issues Proposed Coverage Decision to Broaden Access for Carotid Stenting

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

FDA Advisors Unconvinced by Lutonix BTK Drug-Coated Balloon

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Many Invasive Procedures, Including Cardiovascular, Up Risk of Infective Endocarditis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content